Vital Pulp Treatment in Primary Teeth

Sponsor
University of Maryland, Baltimore (Other)
Overall Status
Recruiting
CT.gov ID
NCT02298504
Collaborator
(none)
156
1
3
54
2.9

Study Details

Study Description

Brief Summary

In primary teeth, decay that is near the pulp (tooth nerve)is treated with either a pulpotomy or indirect pulp treatment if the tooth is not going to be extracted A pulpotomy involves removing the top 1/2 of the pulp, placing a medication/material on the pulp, covering the remaining pulp with a cement, and the restoring the tooth. The purpose of this pilot study is to gain preliminary information regarding the success of Biodentine, MTA, and IPT in the treatment of deep decay in children's primary molars.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Pediatric patients having deep decay in primary molars seen at UMMC, UMSOD, and University of Maryland Rehabilitation and Orthopaedic Institute, will be included in the sample. Teeth with deep caries, >50% into dentin, will be randomly assigned using a table of random numbers to the three treatment groups:

Group 1 pulpotomy with MTA, Group 2 pulpotomy with Biodentine, Group 3 indirect pulp treatment. Treatment will be performed by board certified pediatric dentists or they will directly supervise pediatric dental residents at each site as part of their regular protocol for treating deep caries.

Radiographs will be taken as prescribed in the Guideline for taking Radiographs in Children by the American Academy of Pediatric Dentistry.

Twice yearly clinical examinations will be performed by the treating dentists or pediatric dental residents to check for any soft tissue pathology such as abscess or mobility of treated tooth/teeth. If treatment success/failure consensus between the blinded dentists is not reached, a third dentist will be consulted.

The success/failure data will be entered onto spreadsheets and examined statistically using statistical software.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
156 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of MTA Pulpotomy, Biodentine Pulpotomy, and Glass Ionomer Indirect Pulp Treatment in Primary Teeth
Actual Study Start Date :
Jul 1, 2018
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Indirect pulp cap

IDP will be performed for this group

Device: Vitrebond
Vital pulp therapy
Other Names:
  • Indirect pulp cap
  • Experimental: MTA pulpotomy

    MTA pulpotomy will be performed for this group

    Drug: Mineral Trioxide Aggregate
    Vital pulp therapy
    Other Names:
  • MTA pulpotomy
  • Experimental: Biodentin pulpotomy

    Biodentin pulpotomy will be performed for this group

    Drug: Biodentin
    Vital pulp therapy
    Other Names:
  • Biodentin Pulpotomy
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical success after pulpotomy [3 years]

      No signs of abscess or any swelling related to the tooth, no signs of fistula or other pathology, no signs of pathologic mobility, no post-operative pain, no pain on palpation or percussion of the tooth

    2. Clinical success after indirect pulp cap [3 years]

      No signs of abscess or any swelling related to the tooth, no signs of fistula or other pathology, no signs of pathologic mobility, no post-operative pain, no pain on palpation or percussion of the tooth

    3. Radiographic success after pulpotomy [3 years]

      No signs of root resorption (internal or external), no signs of furcation involvement or periapical radiolucency, no signs of loss of lamina dura, presence of normal appearance of periodontal ligament space

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 9 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Pediatric patients with deep dental decay in primary molars

    • Teeth with signs and symptoms of reversible pulpitis

    Exclusion Criteria:
    • Teeth with clinical symptoms of irriversible pulpitis or pulp necrosis or acute dental infection

    • Children with systemic illness that contraindicated vital pulp treatment such a sickle cell disease

    • Teeth that are not restorable

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Maryland School of Dentistry Baltimore Maryland United States 21043

    Sponsors and Collaborators

    • University of Maryland, Baltimore

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vineet Dhar, Associate Professor, Graduate Program Director, University of Maryland, Baltimore
    ClinicalTrials.gov Identifier:
    NCT02298504
    Other Study ID Numbers:
    • HP-00058711
    First Posted:
    Nov 24, 2014
    Last Update Posted:
    Jan 27, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    Yes

    Study Results

    No Results Posted as of Jan 27, 2022